Nyse jnj compare.

Apr 17, 2023 · From a stock-performance standpoint, Procter & Gamble has held up better than Johnson & Johnson. While PG stock is roughly flat year-to-date and down 1.5% over the last year, JNJ stock is off 6% ...

Nyse jnj compare. Things To Know About Nyse jnj compare.

NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.In addition, the data showed that the …Johnson & Johnson’s (NYSE: JNJ) history of consistently increasing dividends for 61 consecutive years (as of Q3 2023) highlights its payout stability. Dividend payments are critical for income ...JNJ Earnings Date and Information. Johnson & Johnson last announced its quarterly earnings data on October 17th, 2023. The reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.52 by $0.14. The business had revenue of $21.35 billion for the quarter, compared to analysts' …Johnson & Johnson (NYSE:JNJ) is considered by many to be one of the best long-term stocks, due to its consistent high performance throughout many decades of both price and dividend growth. This is ...

As such, its total long-term debt to capitalization ratio is also higher at 36.9% Vs. J&J’s 27.6%. J&J’s interest coverage in the trailing 12 months is 25.69x, much better than Pfizer’s 9 ...24.51%. Dividend Yield. 3.34. The second half of 2022 and the start of 2023 were not kind to shares of Target. Like many other big-box retailers, the impact of inflation and supply chain ...

२०२३ अगस्ट ३१ ... Johnson & Johnson stock (NYSE: JNJ) has seen a 3% fall in a month, compared to a 2% fall for the broader S&P500 index.

Johnson & Johnson ( NYSE: JNJ) on Monday gave more details about its previously announced plans to split off shares of consumer health unit Kenvue ( NYSE: KVUE) through an exchange offer to ...Thus, pharma companies JNJ and MDGL are well-positioned to benefit from the industry’s tailwinds. JNJ has declined 1.5% over the past three months, while MDGL plunged 37.2%. JNJ has slumped 10.7% over the past nine months, compared to MDGL’s 52.3% decline. However, JNJ fell 4% over the past year, while MDGL gained 97.4%.The 71 analysts offering price forecasts for Johnson & Johnson have a median target of 184.06, with a high estimate of 215.00 and a low estimate of 40.00. The median …Johnson & Johnson has a total shareholder equity of $71.2B and total debt of $29.9B, which brings its debt-to-equity ratio to 42%. Its total assets and total liabilities are $166.1B and $94.8B respectively. Johnson & Johnson's EBIT is $27.6B making its interest coverage ratio -78. It has cash and short-term investments of $23.5B.

Apr 18, 2023 · Johnson & Johnson announced its 61st consecutive dividend increase and it raised its 2023 outlook along with beating top and bottom line estimates. Find out why JNJ stock is a Buy.

One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. …

Nov 30, 2023 · The latest price target for Johnson & Johnson ( NYSE: JNJ) was reported by RBC Capital on Friday, December 1, 2023. The analyst firm set a price target for 178.00 expecting JNJ to rise to within ... ABBV has an FY1 P/E ratio of 13.49x, compared to JNJ’s 15.27x. As a result, ABBV's PEG ratio turns out to be 1.55x and JNJ's 2.57x, both higher than the preferred threshold of 1x that Lynch ...Aug 29, 2016 · Using the JNJ investor calculator here, $10,000 investment in JNJ would be valued at $40,028.63 with dividend reinvested. Again, using the same calculator to compute the S&P500 return in the ... Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by London Co. of Virginia marketbeat.com - December 1 at 12:35 PM: Johnson & Johnson (NYSE:JNJ) Given Outperform Rating at Royal Bank of Canada marketbeat.com - December 1 at 12:14 PM: Johnson & Johnson’s (NYSE:JNJ) Revised Earnings Don’t Worry Investors …Apr 17, 2023 · Johnson & Johnson (NYSE:JNJ) is the largest by market cap valuation of what I tend to refer to as the "Big 8" U.S. Pharmas - although perhaps not for much longer. Johnson & Johnson ( NYSE: JNJ) is a global leader in pharmaceuticals and consumer products. Despite logistical and legal headwinds in 1Q23, all segments reported strong growth. JNJ intends to spin ...In this article, we will take a closer look at Johnson & Johnson (NYSE:JNJ) and Pfizer , the two largest US-based pharmaceutical companies by market capitalization. Both are high-quality dividend ...

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more.Even if we look at a longer time frame, AbbVie’s sales growth has been better. It rose at an average annual growth rate of 20.6% to $56.2 billion in 2021, compared to $32.8 billion in 2018 ...Research Johnson & Johnson's (NYSE:JNJ) stock key valuation metrics while comparing it with its industry peers & market side by side.NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of …Price-To-Earnings vs Fair Ratio: JNJ is good value based on its Price-To-Earnings Ratio (26.6x) compared to the estimated Fair Price-To-Earnings Ratio (29x). Analyst Price Targets What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.In addition, the data showed that the …Compared with Eli Lilly, Johnson & Johnson's profit margin of 20.8% is broadly similar. However, J&J's year-over-year quarterly revenue growth is only 3.3%, perhaps as a result of a much larger ...

NYSE: JNJ. Johnson & Johnson. Today's Change. (2.40%) $3.72. Current Price ... What is the Difference Between Simple & Compound Interest? A person looking at a ...Johnson & Johnson (JNJ). NYSE. Symbol. Exchange. Currency. JNJ, NYSE, USD, Real-time ... compared to the 3.7% reading seen in August. Overall, while the trend is.NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.In addition, the data showed that the …NYSE: JNJ. New Brunswick, New Jersey. $158.38 +3.72 (+2.40%) Share Price. as of December 1 4:00:00 PM EST. About Johnson & Johnson. Johnson & Johnson is a holding company, which engages in the ...Oct 7, 2017 · While both Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT) are good companies, ... Hard to compare with JNJ, because MDT is med tech and JNJ is med tech + pharma + consumer goods. JNJ's best-in-class "A+" profitability grade provides robust support in a high-interest rate environment. Its renewed focus on its pharma and medtech business provides further valuation support.Oct 26, 2021 · JNJ is currently trading c.34% higher than the estimated price, hence is overvalued. That being said, JNJ is also known for beating analysts’ estimates. In the last 2 years, JNJ beat analysts ...

२०२१ नोभेम्बर १२ ... ... stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with ...

Apr 3, 2023 · Mario Tama. Introduction. The stock of healthcare stalwart Johnson & Johnson (NYSE:JNJ) has been feeling under the weather of late.Over the last six months, it has delivered negative returns in ...

If JNJ stock closes above 182.50 on the expiration date, the shares will be called away at 182.50, leaving the trader with a total profit of $385 (gain on the shares plus the $300 option premium ...The PE ratio of Johnson & Johnson has averaged 45.3 over the last ten years. The current P/E ratio of 11.12 is 75% lower than the historical average. Looking back at the last ten years, JNJ's PE ratio peaked in the Dec 2017 quarter at 291.08, when the price was $139.72 and the EPS was $0.48. The lowest point was in the Oct 2023 quarter, when it ...Google Finance provides real-time market quotes, international exchanges, up-to-date financial news, and analytics to help you make more informed trading and investment decisions.Apr 3, 2023 · Mario Tama. Introduction. The stock of healthcare stalwart Johnson & Johnson (NYSE:JNJ) has been feeling under the weather of late.Over the last six months, it has delivered negative returns in ... 2. Johnson & Johnson (NYSE: JNJ) On the other end of the scale, Johnson & Johnson is one of the grand old names of American health care services. Founded in 1886, it’s one of the biggest ...Justin Sullivan/Getty Images News. Johnson & Johnson ( JNJ) said Thursday that it could launch an exchange offer for its stake in recently spun-out Kenvue ( NYSE: KVUE) "as early as the coming ...Johnson & Johnson (NYSE: JNJ) will spin out its consumer health unit as Kenvue tomorrow, May 4. The stock will trade on the NYSE under the symbol KVUE. Johnson & Johnson hopes to raise $3.3 ...Johnson & Johnson (NYSE:JNJ) CFO Joseph Wolk and pharmaceuticals division head Jennifer Taubert are reportedly leading contenders for the CEO job in the wake of the unexpected departure of the ...JNJ is currently trading c.34% higher than the estimated price, hence is overvalued. That being said, JNJ is also known for beating analysts’ estimates. In the last 2 years, JNJ beat analysts ...

Overview Key Ratios Peer Comparison Financials Share Holdings Other details Johnson & Johnson (JNJ) Share Price NYSE $151.28 As on 27-Nov-2023 16:10 …Johnson & Johnson (NYSE:JNJ) has seen its shares drop to a new 52-week low this week. The company offers a safe and steadily growing dividend, and its business model makes it resilient versus ...Oct 7, 2017 · While both Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT) are good companies, ... Hard to compare with JNJ, because MDT is med tech and JNJ is med tech + pharma + consumer goods. Johnson & Johnson (JNJ) key stats comparison: compare with other stocks by ... NYSE | $USD | Realtime. Summary · Ratings · Financials · Earnings · Dividends ...Instagram:https://instagram. ginkgo bioworks stock predictionerdmann grouppgolnesm New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board … stock portfolio management toolswhat is a real estate investment firm Johnson & Johnson (NYSE:JNJ) pays an annual dividend of $4.76 per share and currently has a dividend yield of 3.12%. The company has been increasing its dividend for 61 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 35.34%.As such, its total long-term debt to capitalization ratio is also higher at 36.9% Vs. J&J’s 27.6%. J&J’s interest coverage in the trailing 12 months is 25.69x, much better than Pfizer’s 9 ... simulated trading platform The S&P 500 Index ( ^GSPC -0.20%) hit record highs (again) earlier this week, and is up to the tune of 45% over the past 12 months. By contrast, shares of Johnson & Johnson ( JNJ 0.81%) are only ...The 71 analysts offering price forecasts for Johnson & Johnson have a median target of 184.06, with a high estimate of 215.00 and a low estimate of 40.00. The median estimate represents a 86.05 ...This report compares the performances of Johnson & Johnson (JNJ) and GlaxoSmithKline PLC (GSK) stocks. After reading this report, you will learn the differences in growth, annual returns, dividend payouts, splits, biggest gains etc. The timeframe of analysis is between '11-26-2013' and '11-24-2023'. In total, there are 7 sections in this report.